OBJECTIVE: The aim of the study was to determine whether docosahexaenoic acid (DHA) supplementation improves the behavior of children with autism. METHODS:A group of 3- to 10-year-old children with autism were randomized in a double-blind fashion to receive a supplement containing 200 mg of DHA or a placebo for 6 months. The parents and the investigator completed the Clinical Global Impressions-Improvement scale to rate changes in core symptoms of autism after 3 and 6 months. The parents completed the Child Development Inventory and the Aberrant Behavior Checklist, and both parents and teachers completed the Behavior Assessment Scale for Children (BASC) at enrollment and after 6 months. RESULTS: A total of 48 children (40 [83%] boys, mean age [standard deviation] 6.1 [2.0] years) were enrolled; 24 receivedDHA and 24 placebo. Despite a median 431% increase in total plasma DHA levels after 6 months, the DHA group was not rated as improved in core symptoms of autism compared to the placebo group on the CGI-I. Based on the analysis of covariance models adjusted for the baseline rating scores, parents (but not teachers) provided a higher average rating of social skills on the BASC for the children in the placebo group compared to the DHA group (P = 0.04), and teachers (but not parents) provided a higher average rating of functional communication on the BASC for the children in the DHA group compared to the placebo group (P = 0.02). CONCLUSIONS: Dietary DHA supplementation of 200 mg/day for 6 months does not improve the core symptoms of autism. Our results may have been limited by inadequate sample size.
RCT Entities:
OBJECTIVE: The aim of the study was to determine whether docosahexaenoic acid (DHA) supplementation improves the behavior of children with autism. METHODS: A group of 3- to 10-year-old children with autism were randomized in a double-blind fashion to receive a supplement containing 200 mg of DHA or a placebo for 6 months. The parents and the investigator completed the Clinical Global Impressions-Improvement scale to rate changes in core symptoms of autism after 3 and 6 months. The parents completed the Child Development Inventory and the Aberrant Behavior Checklist, and both parents and teachers completed the Behavior Assessment Scale for Children (BASC) at enrollment and after 6 months. RESULTS: A total of 48 children (40 [83%] boys, mean age [standard deviation] 6.1 [2.0] years) were enrolled; 24 received DHA and 24 placebo. Despite a median 431% increase in total plasma DHA levels after 6 months, the DHA group was not rated as improved in core symptoms of autism compared to the placebo group on the CGI-I. Based on the analysis of covariance models adjusted for the baseline rating scores, parents (but not teachers) provided a higher average rating of social skills on the BASC for the children in the placebo group compared to the DHA group (P = 0.04), and teachers (but not parents) provided a higher average rating of functional communication on the BASC for the children in the DHA group compared to the placebo group (P = 0.02). CONCLUSIONS: Dietary DHA supplementation of 200 mg/day for 6 months does not improve the core symptoms of autism. Our results may have been limited by inadequate sample size.
Authors: Chuck T Chen; Joseph A Schultz; Sophie E Haven; Breanne Wilhite; Chi-Hsiu Liu; Jing Chen; Joseph R Hibbeln Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2019-11-20 Impact factor: 4.006
Authors: Kelly W Sheppard; Kelly M Boone; Barbara Gracious; Mark A Klebanoff; Lynette K Rogers; Joseph Rausch; Christopher Bartlett; Daniel L Coury; Sarah A Keim Journal: J Autism Dev Disord Date: 2017-11
Authors: Carlo Agostoni; Maria Nobile; Valentina Ciappolino; Giuseppe Delvecchio; Alessandra Tesei; Stefano Turolo; Alessandro Crippa; Alessandra Mazzocchi; Carlo A Altamura; Paolo Brambilla Journal: Int J Mol Sci Date: 2017-12-04 Impact factor: 5.923
Authors: Hajar Mazahery; Cathryn Conlon; Kathryn L Beck; Marlena C Kruger; Welma Stonehouse; Carlos A Camargo; Barbara J Meyer; Bobby Tsang; Owen Mugridge; Pamela R von Hurst Journal: Trials Date: 2016-06-23 Impact factor: 2.279